In silico drug discovery: Solving the "target-rich and lead-poor" imbalance using the genome-to-drug-lead paradigm

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 1, 2007, Pages 30-34

  Pang, Y P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BOTULINUM TOXIN; CHYMOTRYPSIN LIKE CYSTEINE PROTEINASE; CHYMOTRYPSIN LIKE CYSTEINE PROTEINASE INHIBITOR; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; GLOBULAR PROTEIN; HUMAN SERUM ALBUMIN; NEW DRUG; PROTEIN; PROTEINASE INHIBITOR; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; ZINC ENDOPEPTIDASE INHIBITOR;

AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER ANALYSIS; COMPUTER MODEL; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENOME; MANPOWER; MANPOWER PLANNING; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SARS CORONAVIRUS; SEQUENCE HOMOLOGY; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL GENOMICS; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; UNITED STATES; VIRUS REPLICATION; VIRUS TRANSCRIPTION; X RAY CRYSTALLOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; COMPUTATIONAL BIOLOGY; DRUG DESIGN; GENOME, HUMAN; HUMANS; MODELS, MOLECULAR; PHARMACOGENETICS; PROTEIN CONFORMATION; PROTEINS;

EID: 33845971492     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100030     Document Type: Review

References (20)

1. Venter, J.C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
2. Banks, R.E. et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 356, 1749-1756 (2000).
3. Burley, S.K. et al. Structural genomics: beyond the Human Genome Project. Nat. Genet. 23, 151-157 (1999).
4. Chait, E.M. Drug discovery - contemporary small molecule drug discovery - Tutorial: stacking the deck in favor of drug-like leads. Genet. Eng. News 22, 34-37 (2002).
5. Perola, E. et al. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. J. Med. Chem. 43, 401-408 (2000).
6. Miller, M.A. Chemical database techniques in drug discovery. Nat. Rev. Drug Discov. 1, 220-227 (2002).
7. Sousa, S.F., Fernandes, P.A. & Ramos, M.J. Protein-ligand docking: current status and future challenges. Proteins 65, 15-26 (2006).
8. Hattotuwagama, C.K., Davies, M.N. & Flower, D.R. Receptor-ligand binding sites and virtual screening. Curr Med Chem 13, 1283-1304 (2006).
9. Pang, Y.-P., Perola, E., Xu, K. & Prendergast, F.G. EUDOC: A computer program for identification of drug interaction sites in macromolecules and drug leads from chemical databases. J. Comp. Chem. 22, 1750-1771 (2001).
10. Bradley, P., Misura, K.M. & Baker, D. Toward high-resolution de novo structure prediction for small proteins. Science 309, 1868-1871 (2005).
11. Dooley, A.J., Shindo, N., Taggart, B., Park, J.G. & Pang, Y.-P. From genome to drug lead: identification of a small-molecule inhibitor of the SARS virus. Bioorg. Med. Chem. Lett. 16, 830-833 (2006).
12. Caves, L.S.D., Evanseck, J.D. & Karplus, M. Locally accessible conformations of proteins -multiple molecular dynamics simulations of crambin. Protein Sci. 7, 649-666 (1998).
13. Smith, L.J., Daura, X. & van Gunsteren, W.F. Assessing equilibration and convergence in biomolecular simulations. Proteins 48, 487-496 (2002).
14. Snow, C.D., Nguyen, N., Pande, V.S. & Gruebele, M. Absolute comparison of simulated and experimental protein-folding dynamics. Nature 420, 102-106 (2002).
15. Zagrovic, B., Snow, C.D., Shirts, M.R. & Pande, V.S. Simulation of folding of a small alpha-helical protein in atomistic detail using worldwide-distributed computing. J. Mol. Biol. 323, 927-937 (2002).
16. Oelschlaeger, P., Schmid, R.D. & Pleiss, J. Modeling domino effects in enzymes: molecular basis of the substrate specificity of the bacterial metallo-beta-lactamases IMP-1 and IMP-6. Biochemistry 42, 8945-8956 (2003).
17. Pang, Y.-P. Three-dimensional model of a substrate-bound SARS chymotrypsin-like cysteine proteinase predicted by multiple molecular dynamics simulations: catalytic efficiency regulated by substrate binding. Proteins. 57, 747-757 (2004).
18. Pornillos, O., Alam, S.L., Davis, D.R. & Sundquist, W.I. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat. Struct. Biol. 9, 812-817 (2002).
19. Chen, H. et al. Only one protomer is active in the dimer of SARS 3C-like proteinase. J. Biol. Chem. 281, 13894-13898 (2006).
20. Park, J.G. et al. Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg. Med. Chem. 14, 395-408 (2006).